BFC Planning, Inc.’s Sonoma Pharmaceuticals SNOA Stock Holding History

BFC Planning, Inc.’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5	Closed	-$15	–	2687
2024 Q3	$15	Buy	+5	New	+$26	﹤0.01%	2585

Other funds holding SNOA

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

BFC Planning, Inc.'s SNOA Position: Q4 2024 in Review

BFC Planning, Inc. sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2024, closing a stake of 5 shares — an estimated $15 sold.

BFC Planning, Inc. first reported a position in SNOA in Q3 2024 and held it in 1 quarter. The position peaked at $15 in Q3 2024. 9 funds tracked by Wall St. Rank hold SNOA as of Q4 2024.

BFC Planning, Inc. reported no remaining Sonoma Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
BFC Planning, Inc. sold 5 Sonoma Pharmaceuticals shares in Q4 2024, an estimated $15.
BFC Planning, Inc. first reported a position in Sonoma Pharmaceuticals in Q3 2024 and held it in 1 quarter.
BFC Planning, Inc.'s Sonoma Pharmaceuticals position peaked at $15 in Q3 2024.
9 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2024.

Based on BFC Planning, Inc.'s 13F filing for Q4 2024, filed 29 Oct 2026.